Dublin, Oct. 04, 2016 -- Research and Markets has announced the addition of the "Global Active Pharmaceutical Ingredients (API) Market Analysis 2016 - Forecast to 2022" report to their offering.
This report analyzes the global markets for "Active Pharmaceutical Ingredients (API)". The market assessment is performed through standard and the tailored research methodology approach.
Annual estimations and forecasts are provided from the year 2013 to 2022 for each given segment and sub segments. Market data derived from the authenticated and reliable sources is subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends.
Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, and other activities.
This report provides:
- Market Sizing estimations and forecasts for a minimum of 6 years of all the given segments, sub segments and the regional markets
- Identifying market dynamics (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Regional and country level market analysis
- Competitive landscaping mapping the key common trends
- Company profiling covering the financials, recent activities and the future strategies
- Supply chain trends mapping the recent advancements
- Strategic recommendations for the new entrants
Key Topics Covered:
1 Introduction
2 Executive Summary
3 Market Analysis
4 Porters Five Force Analysis
5 Active Pharmaceutical Ingredient Market by Drug type
6 Active Pharmaceutical Ingredient Market by Therapeutic Area
7 Active Pharmaceutical Ingredient Market by Type
8 Active Pharmaceutical Ingredient Market by Manfacturing Process
9 Geographical Segmentation
10 Vendor Landscaping
11 Company Profiles
- Aurobindo Pharma Ltd.
- Dr. Reddy's Laboratories Ltd.
- Teva Pharmaceutical Industries Limited
- Mylan Inc.
- Sun Pharmaceutical Industries Ltd.
- Lupin
- Allergan PLC
- Novartis International AG
- Albemarle Corporation
- Sigma-Aldrich Corporation
- WuXi AppTec
- BASF SE
- Pfizer, Inc
- Boehringer Ingelheim GmbH
- Ranbaxy
- Boehringer Ingelheim
- Lonza
For more information about this report visit http://www.researchandmarkets.com/research/mrrkmz/global_active
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals


Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
First Western Ship Transits Strait of Hormuz Since Iran War Began
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 



